Prøve GULL - Gratis
RVAC Medicines, A*STAR to build capabilities for mRNA production in Singapore
BioSpectrum Asia
|December 2022
RVAC Medicines, a messenger RNA (mRNA) technology platform startup incubated by CBC Group, a healthcare-dedicated asset management firm headquartered in Singapore, and the Agency for Science, Technology and Research (A*STAR) have announced the signing of a master research collaboration agreement to jointly study and develop solutions to build mRNA manufacturing and analytics capabilities in Singapore.
-
Denne historien er fra December 2022-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia
BioSpectrum Asia
How FemTech Spurt in APAC is Redefining Healthcare
Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.
4 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
China's Colossal Ageing Population and Low Birth Rate Challenge
China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.
2 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"
At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.
7 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area
Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
NTU and NHG Health partner to advance healthcare education in Singapore
NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"
More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.
5 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel
Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
Royalty Pharma on-boards Kenneth Sun as Senior Vice President and Head of Asia
US-based Royalty Pharma ple has announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
Waters launches omniDAWN Multi-Angle Light Scattering (MALS) Photometer
US-based Waters Corporation has announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
South Korea's Cell and Gene Therapy Surge
South Korea's cell and gene therapy (CGT) landscape is highly dynamic, as observed from regulatory approvals, clinical development, and manufacturing activity.
5 mins
BioSpectrum Asia May 2026
Translate
Change font size